Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
作者:
主题词
苯甲酰胺类(Benzamides);骨髓细胞(Bone Marrow Cells);染色体畸变(Chromosome Aberrations);染色体, 人, 22对(Chromosomes, Human, Pair 22);染色体, 人, 9对(Chromosomes, Human, Pair 9);集落形成单位测定(Colony-Forming Units Assay);DNA甲基化(DNA Methylation);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);造血干细胞(Hematopoietic Stem Cells);人类(Humans);原位杂交, 荧光(In Situ Hybridization, Fluorescence);核型分析(Karyotyping);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);肿瘤干细胞(Neoplastic Stem Cells);哌嗪类(Piperazines);启动区, 遗传(Promoter Regions, Genetic);嘧啶类(Pyrimidines);逆转录聚合酶链反应(Reverse Transcriptase Polymerase Chain Reaction);转录, 遗传(Transcription, Genetic);易位, 遗传(Translocation, Genetic)
DOI
10.4161/cbt.240
PMID
12673129
发布时间
2020-09-30
- 浏览20
Cancer biology & therapy
103-8页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文